Harbin Pharmaceutical Group Co Ltd: A Snapshot of Recent Performance and Overview
Harbin Pharmaceutical Group Co Ltd, a prominent player in the health care sector, has recently been in the spotlight due to its performance on the Shanghai Stock Exchange. As of April 23, 2025, the company’s close price stood at 3.71 CNH, reflecting a notable fluctuation over the past year. The stock reached its 52-week high of 4.97 CNH on January 6, 2025, while its lowest point was recorded at 2.54 CNH on July 8, 2024.
With a market capitalization of 8,510,000,000 CNH, Harbin Pharmaceutical Group maintains a significant presence in the pharmaceutical industry. The company’s price-to-earnings ratio is currently 13.98, indicating investor sentiment and market expectations regarding its future earnings potential.
Company Overview
Based in Harbin, China, Harbin Pharmaceutical Group Co Ltd is dedicated to the development and manufacturing of a diverse range of products. The company’s portfolio includes medicines, preparations, Chinese traditional medicines, healthcare products, and biopharmaceuticals. Among its key products are penicillin and calcium gluconate, which are integral to its offerings.
Since its initial public offering on February 1, 1990, Harbin Pharmaceutical Group has established itself as a key player in the pharmaceutical industry. For more detailed information, stakeholders and interested parties can visit the company’s website at www.hayao.com .
Industry and Market Position
Operating within the health care sector, Harbin Pharmaceutical Group is part of the broader pharmaceutical industry. Its strategic focus on both modern and traditional medicines allows it to cater to a wide range of healthcare needs. The company’s listing on the Shanghai Stock Exchange underscores its commitment to transparency and growth within the competitive pharmaceutical landscape.
As the company continues to navigate the challenges and opportunities within the healthcare sector, its performance on the stock market remains a critical indicator of its financial health and strategic direction.